Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment
Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 2, 2025
Glioblastoma
multiforme
(GBM)
is
considered
to
be
one
of
the
most
devastating
brain
tumors
with
a
shorter
life
expectancy.
Several
factors
contribute
dismal
prognosis
GBM
patients
including
complicated
nature
GBM,
ability
tumor
cells
resist
treatment,
and
difficulty
delivering
drugs
because
barriers
like
blood-brain
barrier
(BBB)
blood-tumor
(BTB).
The
unique
challenges
posed
by
BBB
in
therapeutic
agents
have
led
development
innovative
nanotechnology-based
approaches.
By
exploiting
olfactory/trigeminal
pathway,
nanosystems
offer
promising
strategy
for
targeted
drug
delivery
brain,
glioblastoma
particular.
This
review
contemplates
varied
nanocarriers,
polymeric
nanoparticles,
lipid-based
nanosystems,
situ
gel
formulations,
peptide,
stem
cell-based
nanoformulations,
signifying
their
utility
targeting
minimal
systemic
side
effects.
Emerging
trends
gene
therapy
immunotherapy
context
treatment
also
been
discussed.
Since
safety
paramount
aspect
any
product
get
approved,
this
delves
into
toxicological
considerations
associated
intranasal
nanosystems.
Regulatory
aspects
critical
successful
products
are
explored
review.
Overall,
underscores
significant
advancements
nanotechnology
nose-to-brain
its
potential
impact
on
management.
Язык: Английский
Development and In Vitro Characterization of a Voriconazole Loaded Nanoemulsion for Potential Intranasal Drug Delivery
BioNanoScience,
Год журнала:
2025,
Номер
15(2)
Опубликована: Март 11, 2025
Язык: Английский
Phytochemicals Modulate Biosynthesis and Function of Serotonin, Dopamine, and Norepinephrine for Treatment of Monoamine Neurotransmission-Related Psychiatric Diseases
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(7), С. 2916 - 2916
Опубликована: Март 23, 2025
Serotonin
(5-HT),
dopamine
(DA),
and
norepinephrine
(NE)
are
key
monoamine
neurotransmitters
regulating
behaviors,
mood,
cognition.
5-HT
affects
early
brain
development,
its
dysfunction
induces
vulnerability
to
stress,
raising
the
risk
of
depression,
anxiety,
autism
in
adulthood.
These
synthesized
from
tryptophan
tyrosine
via
hydroxylation
decarboxylation,
metabolized
by
oxidase
(MAO).
This
review
aims
summarize
current
findings
on
role
dietary
phytochemicals
modulating
neurotransmitter
biosynthesis,
metabolism,
function,
with
an
emphasis
their
potential
therapeutic
applications
neuropsychiatric
disorders.
Phytochemicals
exert
antioxidant,
neurotrophic,
neurohormonal
activities,
regulate
gene
expression,
induce
epigenetic
modifications.
Phytoestrogens
activate
estrogen
receptors
or
estrogen-responsive
elements
promoter
target
genes,
enhance
transcription
hydroxylase
hydroxylase,
while
inhibiting
that
MAO.
compounds
also
influence
interaction
between
genetic
environmental
factors,
potentially
reversing
dysregulated
neurotransmission
architecture
associated
conditions.
Despite
promising
preclinical
findings,
clinical
remain
challenging.
Advances
nanotechnology
targeted
delivery
systems
offer
solutions
efficacy.
discusses
mechanisms,
challenges,
strategies,
underscoring
need
for
further
research
advance
phytochemical-based
interventions
diseases.
Язык: Английский
Brain Targeting of Mirtazapine Via Transferosome Embedded Thermoresponsive Nasal Gel for Sustained Release and Augmenting Bioavailability
BioNanoScience,
Год журнала:
2025,
Номер
15(2)
Опубликована: Март 26, 2025
Язык: Английский
Novel and Emerging Treatments for Agitation in Schizophrenia and Bipolar Disorder
Healthcare,
Год журнала:
2025,
Номер
13(8), С. 932 - 932
Опубликована: Апрель 18, 2025
Background:
Agitation
is
a
frequent
and
challenging
symptom
in
schizophrenia
bipolar
disorder,
characterized
by
heightened
motor
activity,
emotional
distress,
potential
aggression.
This
most
observed
during
acute
episodes,
representing
significant
burden
on
patients,
caregivers,
healthcare
systems.
leading
cause
of
emergency
department
visits
psychiatric
hospitalizations,
necessitating
prompt
effective
interventions
to
ensure
safety
mitigate
its
far-reaching
impact.
Traditional
treatments,
including
high-potency
antipsychotics
benzodiazepines,
remain
first-line
options
but
are
associated
with
drawbacks
such
as
sedation,
extrapyramidal
symptoms,
tolerance,
limited
applicability
certain
patient
populations,
especially
those
respiratory
or
cardiac
depression
the
elderly.
Non-pharmacologic
strategies
like
de-escalation
techniques
environmental
modifications
invaluable
may
be
impractical
care
settings,
speed
efficiency
critical
emergent
settings.
These
limitations,
onset
symptoms
high-dose
development
tolerance
highlight
gaps
care,
need
for
faster-acting,
safer,
more
patient-friendly
alternatives
that
reduce
reliance
physical
restraints
invasive
interventions.
Methods:
review
explores
evolution
treatments
agitation,
focusing
alternative
innovative
approaches.
To
these
an
extensive
literature
was
conducted
utilizing
PubMed,
Google
Scholar,
Embase.com,
other
search
engines.
Results:
Key
developments
include
sublingual
dexmedetomidine,
recently
FDA-approved,
which
offers
sedation
without
non-invasive
administration
route.
Similarly,
subcutaneous
olanzapine
provides
convenient
intramuscular
injections,
reducing
injection-related
complications.
Other
emerging
gabapentin,
pregabalin,
ketamine
show
promise
addressing
agitation
specific
contexts,
comorbid
conditions
treatment-resistant
cases.
A
comparative
analysis
therapies
highlights
their
mechanisms
action,
clinical
evidence,
practical
challenges.
Conclusions:
Future
directions
emphasize
intranasal
delivery
systems,
novel
pharmacologic
agents,
roles
cannabinoids
managing
agitation.
innovations
aim
balance
rapid
control
improved
experience.
The
set
back
lack
standardized
dosing
protocols.
They
also
face
ethical
concerns,
chance
misuse
abuse,
well
regulatory
barriers,
they
FDA
approval
legality
changes
between
states.
underscores
clinical,
practical,
considerations
advancing
agitated
paving
way
compassionate
management
Язык: Английский
Remote-Controlled Wireless Bioelectronics for Fluoxetine Therapy to Promote Wound Healing in a Porcine Model
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 21, 2024
Abstract
Wound
healing
presents
a
significant
challenge
in
biomedical
science,
requiring
precise
therapeutic
delivery
and
real-time
monitoring.
Bioelectronic
systems
offer
promising
solution
but
remain
largely
unexplored
for
wound
care,
particularly
large
animal
models
that
reflect
human
dynamics.
This
study
introduces
remote
controlled
wireless
bioelectronic
platform
equipped
with
an
iontophoretic
pump
to
deliver
fluoxetine,
selective
serotonin
reuptake
inhibitor
promotes
repair.
In
vitro
ex-vivo
testing
validated
efficient
on
demand
fluoxetine
delivery.
vivo
experiments
porcine
model
demonstrated
clear
efficacy
over
3-day
7-day
periods.
The
system
enhanced
outcomes,
increasing
re-epithelialization
by
37%
(H&E
staining),
reducing
the
M1/M2
macrophage
ratio
33%,
stimulating
neuronal
growth
at
site.
delivers
controlled,
remotely-controlled
manner
while
allowing
direct
imaging
can
be
used
monitor
progress.
Additionally,
it
allows
dose
temporal
of
treatment
enhance
outcome
future
studies.
Язык: Английский